IMUX
Immunic, Inc. NASDAQ Listed Apr 17, 2014$11.65
Mkt Cap $115.0M
52w Low $5.06
65.6% of range
52w High $15.10
50d MA $11.15
200d MA $8.65
P/E (TTM)
-1.6x
EV/EBITDA
-0.7x
P/B
—
Debt/Equity
-0.1x
ROE
1456.2%
P/FCF
-1.0x
RSI (14)
—
ATR (14)
—
Beta
1.37
50d MA
$11.15
200d MA
$8.65
Avg Volume
421.4K
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.
1200 Avenue of the Americas · New York City, NY 10036 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | BMO | — | — | — | 11.02 | -0.9% | +6.6% | — | — | — | — | — |
| Feb 26, 2026 | BMO | -0.90 | -1.20 | -33.3% | 9.48 | +0.0% | +7.6% | +11.8% | +12.9% | +23.4% | +17.1% | — |
| Nov 13, 2025 | BMO | -0.18 | -0.13 | +27.8% | 7.13 | -0.4% | +9.3% | +2.4% | +6.6% | +0.0% | -3.5% | — |
| Aug 7, 2025 | BMO | -0.18 | -0.20 | -11.1% | 9.02 | +3.1% | -3.3% | -5.9% | -5.5% | -8.1% | +1.6% | — |
| May 15, 2025 | BMO | -0.25 | -0.25 | +0.0% | 9.96 | +0.4% | -3.5% | -3.5% | -2.2% | -7.6% | -7.5% | — |
| Mar 31, 2025 | BMO | -0.22 | -0.25 | -13.6% | 10.90 | +2.8% | -1.8% | +1.8% | -3.7% | -8.7% | -13.5% | — |
| Nov 7, 2024 | BMO | -0.22 | -0.24 | -9.1% | 11.80 | +2.5% | +0.0% | +4.2% | -2.5% | -0.8% | -7.6% | — |
| Aug 8, 2024 | BMO | -0.23 | -0.21 | +8.7% | 13.40 | +0.7% | -0.7% | -0.7% | -0.7% | -3.0% | +0.7% | — |
| May 9, 2024 | BMO | -0.27 | -0.25 | +7.4% | 12.40 | +0.0% | +2.4% | +0.8% | +3.2% | +4.8% | +0.8% | — |
| Feb 22, 2024 | BMO | -0.51 | -0.48 | +5.9% | 12.20 | -0.8% | +0.0% | +4.9% | +13.9% | +14.8% | +20.5% | — |
| Nov 14, 2023 | BMO | -0.55 | -0.51 | +7.3% | 9.90 | +2.0% | +1.0% | +4.0% | +7.1% | +12.1% | +7.6% | — |
| Aug 3, 2023 | BMO | -0.52 | -0.54 | -3.8% | 21.30 | +4.2% | -5.6% | -11.3% | -7.5% | -14.6% | -11.7% | — |
| May 11, 2023 | BMO | -0.54 | -0.58 | -7.4% | 18.20 | -5.5% | -4.4% | -3.3% | -6.6% | -0.5% | -2.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 15 | D. Boral Capital | Downgrade | Buy → Hold | — | $11.80 | $10.80 | -8.5% | -5.9% | -15.3% | -15.3% | -19.1% | -23.6% |
| Mar 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.20 | $9.90 | -2.9% | +3.9% | +4.9% | +14.7% | +8.8% | +20.6% |
| Feb 13 | D. Boral Capital | Maintains | Buy → Buy | — | $8.70 | $11.30 | +29.9% | +4.9% | +5.4% | +0.8% | +12.1% | +8.0% |
| Feb 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.20 | $6.30 | +1.6% | +15.2% | +28.2% | +19.7% | +40.3% | +47.3% |
| Jan 7 | D. Boral Capital | Maintains | Buy → Buy | — | $6.24 | $6.44 | +3.2% | +10.6% | +6.2% | +6.6% | +6.1% | +8.5% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.13 | $7.10 | -0.4% | +9.3% | +2.4% | +6.6% | +0.0% | -3.5% |
| Nov 13 | D. Boral Capital | Maintains | Buy → Buy | — | $7.60 | $7.80 | +2.6% | -6.2% | +2.5% | -3.9% | +0.0% | -6.2% |
| Sep 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.98 | $9.10 | +1.3% | +4.6% | +4.1% | -1.8% | +6.9% | +7.2% |
| Sep 25 | D. Boral Capital | Maintains | Buy → Buy | — | $8.79 | $8.70 | -1.0% | +2.2% | +6.8% | +6.4% | +0.3% | +9.2% |
| Aug 8 | D. Boral Capital | Maintains | Buy → Buy | — | $9.02 | $9.30 | +3.1% | -3.3% | -5.9% | -5.5% | -8.1% | +1.6% |
| Jun 25 | D. Boral Capital | Maintains | Buy → Buy | — | $7.08 | $7.20 | +1.7% | -1.0% | +0.3% | -1.1% | -1.4% | -2.5% |
| Jun 5 | D. Boral Capital | Maintains | Buy → Buy | — | $7.75 | $8.50 | +9.7% | -0.3% | +1.7% | +11.9% | +14.2% | +12.3% |
| May 29 | D. Boral Capital | Maintains | Buy → Buy | — | $9.10 | $8.00 | -12.1% | -25.3% | -27.5% | -23.1% | -19.8% | -14.8% |
| May 23 | B. Riley Securities | Maintains | Buy → Buy | — | $9.21 | $9.10 | -1.2% | -0.3% | -3.4% | -1.2% | -26.2% | -28.3% |
| May 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.90 | $10.20 | +3.0% | +18.2% | +16.2% | +13.1% | +8.1% | -0.5% |
| Apr 30 | D. Boral Capital | Maintains | Buy → Buy | — | $12.80 | $12.50 | -2.3% | -22.7% | -8.6% | -10.2% | -12.5% | -16.4% |
| Apr 16 | B. Riley Securities | Maintains | Buy → Buy | — | $9.88 | $10.00 | +1.2% | -4.6% | -0.8% | +0.1% | +1.2% | +11.3% |
| Apr 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.18 | $9.10 | -0.9% | +7.6% | +2.7% | +6.8% | +7.7% | +8.9% |
| Apr 10 | D. Boral Capital | Maintains | Buy → Buy | — | $9.25 | $9.90 | +7.0% | -4.4% | -2.7% | -0.8% | +6.8% | +1.9% |
| Apr 1 | D. Boral Capital | Maintains | Buy → Buy | — | $10.90 | $11.20 | +2.8% | -1.8% | +1.8% | -3.7% | -8.7% | -13.5% |
| Feb 26 | D. Boral Capital | Maintains | Buy → Buy | — | $11.50 | $11.90 | +3.5% | +1.7% | -2.6% | +3.5% | +0.9% | +1.7% |
| Feb 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.80 | $12.10 | +2.5% | +7.6% | +1.7% | -2.5% | -0.8% | -5.1% |
| Feb 20 | D. Boral Capital | Maintains | Buy → Buy | — | $10.50 | $10.90 | +3.8% | +12.4% | +21.0% | +14.3% | +9.5% | +11.4% |
| Jan 7 | D. Boral Capital | Maintains | Buy → Buy | — | $10.90 | $11.20 | +2.8% | +2.8% | +0.9% | -3.7% | -1.8% | -8.3% |
| Nov 7 | EF Hutton | Maintains | Buy → Buy | — | $11.80 | $11.70 | -0.8% | +0.0% | +0.0% | +4.2% | -2.5% | -0.8% |
| Oct 22 | EF Hutton | Maintains | Buy → Buy | — | $15.50 | $17.00 | +9.7% | -9.7% | -7.7% | -11.0% | -10.3% | -13.5% |
| Sep 18 | EF Hutton | Maintains | Buy → Buy | — | $16.10 | $16.80 | +4.3% | +11.2% | +21.1% | +13.7% | -0.6% | -3.1% |
| Jul 16 | Piper Sandler | Maintains | Overweight → Overweight | — | $13.60 | $13.60 | +0.0% | +8.8% | +7.4% | +0.7% | +3.7% | +7.4% |
| Oct 10 | Wedbush | Maintains | Outperform → Outperform | — | $15.90 | $19.15 | +20.4% | -13.8% | -11.3% | -22.6% | -23.9% | -22.6% |
| Jul 27 | Wedbush | Maintains | Outperform → Outperform | — | $21.80 | $22.40 | +2.8% | -6.4% | +8.7% | +10.6% | +6.9% | -0.9% |
| Oct 21 | SVB Leerink | Downgrade | Outperform → Market Perform | — | $92.00 | $24.20 | -73.7% | -77.4% | -81.5% | -81.5% | -79.9% | -80.4% |
| Aug 8 | Aegis Capital | Maintains | Buy → Buy | — | $53.30 | $53.30 | +0.0% | -4.1% | -5.8% | -3.6% | -7.7% | -1.5% |
| Jun 3 | SVB Leerink | Maintains | Outperform → Outperform | — | $31.40 | $29.70 | -5.4% | +8.0% | +7.6% | +21.0% | +27.4% | +24.5% |
| May 18 | Piper Sandler | Maintains | Overweight → Overweight | — | $65.10 | $62.70 | -3.7% | -11.7% | -15.8% | -11.4% | -7.5% | -7.1% |
| Sep 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $101.00 | $100.40 | -0.6% | -5.1% | -5.3% | -4.2% | -6.6% | -4.2% |
| Apr 15 | Aegis Capital | Maintains | Buy → Buy | — | $145.20 | $146.50 | +0.9% | +6.3% | -2.1% | -7.4% | -11.1% | -3.0% |
| Mar 24 | JMP Securities | Maintains | Market Outperform → Outperform | — | $145.90 | $157.40 | +7.9% | -2.6% | -1.5% | +1.1% | -2.6% | +0.4% |
| Oct 2 | SVB Leerink | Maintains | Outperform → Outperform | — | $188.70 | $192.30 | +1.9% | +0.2% | +3.8% | -0.4% | +2.2% | +2.4% |
| Aug 26 | Piper Sandler | Maintains | Overweight → Overweight | — | $144.20 | $183.20 | +27.0% | +16.2% | +9.9% | +10.6% | +11.3% | +5.5% |
| Aug 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $187.00 | $185.80 | -0.6% | -1.4% | -18.2% | -22.9% | -10.4% | -15.2% |
| Aug 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $172.00 | $219.20 | +27.4% | +27.9% | +13.0% | +4.9% | +6.5% | +8.7% |
| Jul 20 | BMO Capital | Maintains | Outperform → Outperform | — | $135.20 | $147.40 | +9.0% | +12.1% | +22.4% | +25.4% | +20.4% | +16.7% |
| Jun 5 | Wedbush | Maintains | Outperform → Outperform | — | $114.10 | $129.40 | +13.4% | +14.1% | +20.7% | +12.2% | +4.2% | -6.7% |
| May 11 | H.C. Wainwright | Maintains | Buy → Buy | — | $86.00 | $97.70 | +13.6% | +16.4% | +24.4% | +18.4% | +25.3% | +14.5% |
| Aug 12 | Chardan Capital | Maintains | Buy → Buy | — | $130.10 | $132.00 | +1.5% | +2.5% | +4.2% | +1.7% | +2.3% | +3.8% |
| Jul 11 | Chardan Capital | Maintains | Buy → Buy | — | $109.40 | $127.40 | +16.5% | +28.4% | +27.2% | +27.5% | +19.7% | +32.5% |
No insider trades available.
8-K · 5.02
!!! Very High
Immunic, Inc. -- 8-K 5.02: Executive Change
Immunic appointed Michael A. Panzara as Chief Medical Officer and director effective April 24, 2026, strengthening its medical leadership while simultaneously resigning from a prior directorship role.
Apr 28
8-K · 8.01
!! High
Immunic, Inc. -- 8-K 8.01: Material Event / Announcement
Immunic implemented a reverse stock split effective April 23, 2026, which consolidates shares to potentially improve stock price perception, though it does not change underlying company value or alter shareholder ownership percentages.
Apr 23
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
IMUX's 1-for-10 reverse stock split, effective April 27, 2026, consolidates shares to improve stock price perception and maintain exchange listing compliance, though it doesn't change fundamental value and typically signals financial distress.
Apr 14
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
IMUX's retention bonus structure suggests leadership instability or transition risk, potentially signaling management uncertainty that could pressure the stock pending clarity on strategic direction.
Apr 10
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
IMUX regained Nasdaq compliance after falling below minimum bid price, eliminating imminent delisting risk and restoring institutional investment eligibility, supporting near-term stock stability.
Apr 1
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Multiple executive departures at IMUX and MLYS effective March 27, 2026, signal potential leadership instability that could disrupt strategic execution and warrant caution on both stocks.
Mar 31
8-K
Immunic, Inc. -- 8-K Filing
Immunic reported 2025 year-end financial results and corporate updates for its late-stage oral therapy programs targeting neurologic and gastrointestinal diseases, signaling progress in its clinical pipeline.
Feb 26
8-K · 1.01
! Medium
Immunic, Inc. -- 8-K 1.01: Equity Issuance
Immunic secured a $200 million equity issuance agreement, potentially strengthening its cash position for pipeline development and operations.
Feb 13
Data updated apr 25, 2026 3:24pm
· Source: massive.com